SEC Form EFFECT filed by Scorpius Holdings Inc.
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | August 6, 2024 5:30 P.M. |
Form: | S-1 | ||||||
|
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | August 6, 2024 5:30 P.M. |
Form: | S-1 | ||||||
|
8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
10-Q - Scorpius Holdings, Inc. (0001476963) (Filer)
8-K - Scorpius Holdings, Inc. (0001476963) (Filer)
SC 13G - Scorpius Holdings, Inc. (0001476963) (Subject)
SC 13G - Scorpius Holdings, Inc. (0001476963) (Subject)
SC 13D/A - Scorpius Holdings, Inc. (0001476963) (Subject)
4 - Scorpius Holdings, Inc. (0001476963) (Issuer)
DURHAM, N.C., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced that it has been selected to join the Medical CBRN Defense Consortium (MCDC), a key organization advancing the development of medical countermeasures and related technologies to protect U.S. military personnel and civilians from chemical, biological, radiological, and nuclear (CBRN) threats. The MCDC, established in 2015 under the U.S. Department of Defense (DoD), serves as a collaborative framework for government, industry, and academia to partner on cutting-edge medical solu
DURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE:SCPX) ("Scorpius" or the "Company"), an integrated contract development and manufacturing organization (CDMO), today announced the appointment of Shari Udoff-McDonald as VP of Business Development. She brings more than 25 years of experience in biopharma business development and management. Prior to joining Scorpius, Ms. Udoff-McDonald spent 17 years at BioReliance Corporation, part of MilliporeSigma. She was most recently Head of Commercial, North America, East with interim oversight of half of the European market. Her role included commercial oversight of biologics, vaccines, cell and gene therapies, ADCs, and
However, there can be no assurance that that the Reverse Stock Split will increase the Company's stock price sufficiently in order to meet any requirements and policies of the NYSE American. The Reverse Stock Split will take legal effect at 11:01 P.M. Eastern Time on July 17, 2024, and the Company's Common Stock will open for trading on the OTC Markets on July 18, 2024, on a post-split basis, under the existing ticker symbol "SCPX" but with new CUSIP number 42237K508.
Shares of Ovid Therapeutics Inc (NASDAQ:OVID) dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endpoint. Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). AMMO shares dipped 19.1% to $2.0306 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Interactive Strength Inc. (NASDAQ:TRNR) shares climbed 148% to $7.07 after dipping 19% on Friday. Mustang Bio, Inc. (NASDAQ:MBIO) shares jumped 145% to $0.32 after the company announced safety and efficacy da
U.S. stocks traded mixed this morning, with the Dow Jones index falling more than 100 points on Monday. Following the market opening Monday, the Dow traded down 0.34% to 38,456.60 while the NASDAQ rose 0.11% to 17,707.96. The S&P 500 also fell, dropping, 0.12% to 5,425.29. Check This Out: Top 4 Risk Off Stocks That May Rocket Higher In Q2 Leading and Lagging SectorsCommunication services shares jumped by 0.6% on Monday. In trading on Monday, industrials shares fell by 1%. Top Headline The NY Empire State Manufacturing Index rose to -6 in June versus a reading of -15.6 in May and coming in better than market expectations of -12.50. Equities Trading UP
DURHAM, N.C., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced that it has been selected to join the Medical CBRN Defense Consortium (MCDC), a key organization advancing the development of medical countermeasures and related technologies to protect U.S. military personnel and civilians from chemical, biological, radiological, and nuclear (CBRN) threats. The MCDC, established in 2015 under the U.S. Department of Defense (DoD), serves as a collaborative framework for government, industry, and academia to partner on cutting-edge medical solu
DURHAM, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced it has signed a contract to provide bioanalytical services for a publicly traded clinical-stage immuno-oncology company. This collaboration opens the door for further opportunities, as Scorpius expects to expand its services to include additional analytical work and future GMP manufacturing upon completion of this initial phase. This contract underscores Scorpius' expertise in delivering critical bioanalytical and process development services, further establishing its role a
Scorpius Poised to Support Expanded U.S. Government-Backed Project Pipeline as U.S. Drugmakers Seek to Shift to Domestic Suppliers Amid Industry-Changing Legislation DURHAM, N.C., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today commended the U.S. House of Representatives on the passage of the BIOSECURE Act (the "Act"), a pivotal piece of legislation passed with strong bipartisan support following a 306-81 vote earlier this week. The Act is designed to ensure the security of America's pharmaceutical supply chain, strengthen national biosecuri